within Pharmacolibrary.Drugs.ATC.L;

model L01EN04
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.38,
    Cl             = 0.00032166666666666666,
    adminDuration  = 600,
    adminMass      = 20 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.159,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.010166666666666666,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.03,
    k12             = 18.4,
    k21             = 18.4
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01EN04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Futibatinib is an oral, selective, irreversible inhibitor of fibroblast growth factor receptors (FGFR) used in the treatment of cholangiocarcinoma and other solid tumors with FGFR2 gene fusions or rearrangements. It is approved for use as a targeted therapy in patients with previously treated, unresectable, locally advanced, or metastatic intrahepatic cholangiocarcinoma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult cancer patients (median age ~59 years) with intrahepatic cholangiocarcinoma, after oral administration of futibatinib 20 mg once daily under fasting conditions.</p><h4>References</h4><ol><li><p>Bahleda, R, et al., &amp; Arkenau, HT (2020). Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1-4 inhibitor in patients with advanced solid tumors. <i>Annals of oncology : official journal of the European Society for Medical Oncology</i> 31(10) 1405–1412. DOI:<a href=\"https://doi.org/10.1016/j.annonc.2020.06.018\">10.1016/j.annonc.2020.06.018</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32622884/\">https://pubmed.ncbi.nlm.nih.gov/32622884</a></p></li><li><p>Gao, L, et al., &amp; Wacheck, V (2023). A phase I, open-label, single-dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib. <i>Clinical and translational science</i> 16(9) 1713–1724. DOI:<a href=\"https://doi.org/10.1111/cts.13585\">10.1111/cts.13585</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37553804/\">https://pubmed.ncbi.nlm.nih.gov/37553804</a></p></li><li><p>Yamamiya, I, et al., &amp; Benhadji, KA (2023). Evaluation of the Mass Balance and Metabolic Profile of Futibatinib in Healthy Participants. <i>Clinical pharmacology in drug development</i> 12(9) 927–939. DOI:<a href=\"https://doi.org/10.1002/cpdd.1271\">10.1002/cpdd.1271</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37300358/\">https://pubmed.ncbi.nlm.nih.gov/37300358</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01EN04;
